Article

ForbesForbes on 2021-09-02 13:00

What’s Next For Alkermes Stock After A 16% Rise Last Month?

The stock price of Alkermes, a biopharmaceutical company focused on neuroscience and oncology, has seen a rise of around 16% over the last twenty-one ...

Related news